These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21897884)

  • 1. Regulations and guidelines governing stem cell based products: Clinical considerations.
    George B
    Perspect Clin Res; 2011 Jul; 2(3):94-9. PubMed ID: 21897884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Stem Cell-Based Research in India in Comparison with the US, EU and other Asian Countries: Current Issues and Future Perspectives.
    Jose J; George T; Thomas AM
    Curr Stem Cell Res Ther; 2020; 15(6):492-508. PubMed ID: 32250233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
    Xie YM; Tian F
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulations applicable to plant food supplements and related products in the European Union.
    Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
    Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Clinical Research for Cellular and Gene Therapy Products in India.
    Dalal V; Lata H; Kharkwal G; Jotwani G
    Adv Exp Med Biol; 2023; 1430():135-154. PubMed ID: 37526846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Legal regulation of the production and trade of medical devices and medical equipment in the EU and US: experience for Ukraine.
    Pashkov V; Kotvitska A; Harkusha A
    Wiad Lek; 2017; 70(3 pt 2):614-618. PubMed ID: 28713093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.